Scenarios of future mpox outbreaks among men who have sex with men: a modelling study based on cross-sectional seroprevalence data from the Netherlands, 2022
Authors:
- Marc C ShamierMSMarc C Shamier
- Luca M ZaeckLZLuca M Zaeck
- Hannelore M GötzHGHannelore M Götz
- Babs E VerstrepenBVBabs E Verstrepen
- Matthijs Ra WelkersMWMatthijs Ra Welkers
- Elske HoornenborgEHElske Hoornenborg
- Brigitte Agl van CleefBCBrigitte Agl van Cleef
- Martin E van RoyenMRMartin E van Royen
- Kai J JonasKai J Jonas
- Marion Pg KoopmansMKMarion Pg Koopmans
Open Access
- 25 April 2024
- journal article
- research article
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (17) , 2300532
Abstract
Background: Following the 2022–2023 mpox outbreak, crucial knowledge gaps exist regarding orthopoxvirus-specific immunity in risk groups and its impact on future outbreaks. Aim: We combined cross-sectional seroprevalence studies in two cities in the Netherlands with mathematical modelling to evaluate scenarios of future mpox outbreaks among men who have sex with men (MSM). Methods: Serum samples were obtained from 1,065 MSM attending Centres for Sexual Health (CSH) in Rotterdam or Amsterdam following the peak of the Dutch mpox outbreak and the introduction of vaccination. For MSM visiting the Rotterdam CSH, sera were linked to epidemiological and vaccination data. An in-house developed ELISA was used to detect vaccinia virus (VACV)-specific IgG. These observations were combined with published data on serial interval and vaccine effectiveness to inform a stochastic transmission model that estimates the risk of future mpox outbreaks. Results: The seroprevalence of VACV-specific antibodies was 45.4% and 47.1% in Rotterdam and Amsterdam, respectively. Transmission modelling showed that the impact of risk group vaccination on the original outbreak was likely small. However, assuming different scenarios, the number of mpox cases in a future outbreak would be markedly reduced because of vaccination. Simultaneously, the current level of immunity alone may not prevent future outbreaks. Maintaining a short time-to-diagnosis is a key component of any strategy to prevent new outbreaks. Conclusion: Our findings indicate a reduced likelihood of large future mpox outbreaks among MSM in the Netherlands under current conditions, but emphasise the importance of maintaining population immunity, diagnostic capacities and disease awareness.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- Impact of vaccination and high-risk group awareness on the mpox epidemic in the United States, 2022–2023: a modelling studyeClinicalMedicine, 2024
- Mpox in people with past infection or a complete vaccination course: a global case seriesThe Lancet Infectious Diseases, 2023
- Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individualsCell Host & Microbe, 2023
- Two individuals with potential monkeypox virus reinfectionThe Lancet Infectious Diseases, 2023
- Smallpox vaccination‐elicited antibodies cross‐neutralize 2022‐Monkeypox virus Clade IIJournal of Medical Virology, 2023
- Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational studyThe Lancet Infectious Diseases, 2023
- Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccinationJournal of Infection, 2022
- Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus InfectionsCell, 2016
- Modelling the effect of a booster vaccination on disease epidemiologyJournal of Mathematical Biology, 2005
- Human monkeypox: an emerging zoonosisThe Lancet Infectious Diseases, 2004